The drive to defeat pediatric brain cancer intensified this week, as the Children’s Hospital of Philadelphia (CHOP) announced receipt of a $1 million grant from the Children’s Cancer Research Fund on November 18, 2026. The funds will launch an early-phase clinical trial led by Dr. Jessica B. Foster, targeting diffuse midline glioma (DMG)—one of the most devastating and intractable childhood brain tumors.

DMG is notorious for its bleak prognosis and resistance to existing therapies. The new trial will explore a novel immunotherapy approach, aiming to break through the barriers that have kept curative treatments out of reach for so many families. The grant, under the Accelerating Hope Award, comes at a pivotal moment for the field: fresh funding and shifting research strategies are converging to attack pediatric brain tumors from multiple directions, yet the outcome and potential of these efforts stand to be determined by results from initiatives like the one at CHOP.

This funding surge is part of a broader transformation in childhood brain tumor research. The Pediatric Brain Tumor Foundation recently announced its 2026–2027 Research Program, emphasizing integration of artificial intelligence and machine learning into precision medicine, effective therapies, and survivorship outcomes. Letters of intent for these competitive grants are due by September 18, 2026, with full proposals required in January 2027. The Foundation’s strategy is to catalyze innovation that brings new treatments to the clinic—and ultimately, to young patients.

At the same time, longstanding clinical trial networks are seeing major changes. In August 2025, the National Cancer Institute announced funding for the Pediatric Brain Tumor Consortium would end after March 2026. Early-phase trials, a critical pipeline for new drugs and therapies, are transitioning to the Pediatric Early Phase Clinical Trials Network, which spans more than 40 sites in the U.S. Whether this transition will improve clinical trial access and effectiveness is being closely watched by advocates and researchers.

Other organizations, such as the Children’s Brain Tumor Network (CBTN) and IronMatt, continue to bolster the research ecosystem. CBTN is expanding global collaboration and delivering open biosamples and data to scientists worldwide, while IronMatt has awarded over $9.3 million for 102 research projects across North America.

For families facing a diagnosis of pediatric brain cancer, these grant announcements and structural changes represent hope—but also uncertainty. The impact of these investments will only become clear as trials launch, results emerge, and network transitions settle. Yet the commitments made this week underscore a resolve to speed progress for children with brain tumors and to answer urgent calls for new, life-saving therapies.